Home › Research › TREM2 and immune genetics
A cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer's disease
Yoo Y, Neumayer G, Shibuya Y, Mader MM, Wernig M.. Cell stem cell, 2023-08-01
Topic: Brain proteins, microglia and lab models
Alzheimer's disease (AD) remains one of the grand challenges facing human society. Much controversy exists around the complex and multifaceted pathogenesis of this prevalent disease. Given strong human genetic evidence, there is little doubt, however, that microglia play an important role in preventing degeneration of neurons.
Key findings
- Much controversy exists around the complex and multifaceted pathogenesis of this prevalent disease.
- Given strong human genetic evidence, there is little doubt, however, that microglia play an important role in preventing degeneration of neurons.
- For example, loss of function of the microglial gene Trem2 renders microglia dysfunctional and causes an early-onset neurodegenerative syndrome, and Trem2 variants are among the strongest genetic risk factors for AD.
- Thus, restoring microglial function represents a rational therapeutic approach.
Why it matters
This paper describes a cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer's disease, based on genetic evidence that microglia help prevent neuron degeneration. It is animal work and does not show a treatment or cure for people.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 51/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Cell stem cell) |
| Journal's citation record | 3 / 4 | Cell stem cell: journal h-index 372 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “mouse”) — scores zero |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 106 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 21.2 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 4 / 6 | Cited 8.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 3 / 4 | Cited 100 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Marius Wernig: h-index 76 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37541210) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Yoo, Y., Neumayer, G., Shibuya, Y., Mader, M. M., & Wernig, M. (2023). A cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer's disease. Cell stem cell. https://doi.org/10.1016/j.stem.2023.07.006
Vancouver
Yoo Y, Neumayer G, Shibuya Y, Mader MM, Wernig M. A cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer's disease. Cell stem cell. 2023. doi:10.1016/j.stem.2023.07.006. PMID: 37541210.
BibTeX
@article{yoo2023-37541210,
author = {Yoo, Y. and Neumayer, G. and Shibuya, Y. and Mader, M. M. and Wernig, M.},
title = {{A cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer's disease}},
journal = {Cell stem cell},
year = {2023},
doi = {10.1016/j.stem.2023.07.006},
pmid = {37541210},
url = {https://doi.org/10.1016/j.stem.2023.07.006}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 32.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.